OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	255
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	232
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	148
Addressing and overcoming disparities in GVHD	135
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	130
On a collision course: SARS-CoV-2 variants and CAR T cells	127
Cortisol in sickle cell disease: a systematic review and meta-analysis	120
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	120
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	118
A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.	117
Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease	108
Transfusion therapy for sickle cell disease: what’s new?	107
Best but not perfect: indirect measure of low iron stores	100
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	100
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	95
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	92
Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study	90
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	89
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv.	86
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	86
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv.	85
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood	83
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	82
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	81
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	81

Steroid tapering after GVHD Rx: not too fast, not too slow	79
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	78
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	77
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	77
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	77
Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria	75
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	72
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	69
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	69
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma	69
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	68
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	66
CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo	66
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses	65
Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation	65
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	64
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	62
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel	62
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	61
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	61
Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma	59
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction	59
Regional brain age is decreased in children with sickle cell anemia	58
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel	58
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	58
Complement C5 inhibition in early onset HELLP syndrome	57
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	57
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	57
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019	57
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	57
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma	56
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	56
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	56
Gilteritinib + chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial	56
Bite-size introduction to canine hematologic malignancies	56